Delayed Hematuria After Prostatic Photovaporization: Risk Factors to Know

Overview

Journal World J Urol

Specialty Urology

Date 2024 Jul 21

PMID 39033469

Authors

Ali Bourgi

Franck Bruyere

Affiliations

Soon will be listed here.

Abstract

Objective: characterize delayed hematuria (DH) after photoselective vaporization of the prostate (PVP) and identify its associated risk factors.

Methods: 1014 patients who underwent PVP at an expert center, from September 2005 through December 2021, were prospectively enrolled in a database registry. Risk factors of DH included age, prostate volume, ASA score, history of BPH surgery, history of prostate cancer, use of anticoagulation or 5ARIs, concomitant procedure, operative factors, and the duration of follow-up.

Results: The median operating time was 60 ± 11 min. The median specific applied energy was 318,500 Joules ± 101,347. After PVP, the mean catheterization duration was 1.6 days with a postoperative hospitalization time of 1.8 days. The median follow-up was 52 months (range 2-95 months). Hematuria occurred in 206 patients (20.3%), with 10% requiring an ER visit and 8.3% requiring hospital admission, transfusion or endoscopic clot removal. Almost 80% of hematuria episodes occurred within the first 3 months. The overall retreatment rate for clot retention was 3.7% after a mean time of 50 months. Hematuria-free survival was 97.2% after 1 year, and 89.3% after 4 years. Delayed hematuria occurred in 32 patients (3.1%). In the multivariate analysis, age, preoperative prostate volume, anticoagulant use, total applied energy, lasing time and operative time were identified as risk factors for delayed hematuria after PVP.

Conclusion: Larger prostate volume, longer operative time, longer lasing time, and use of oral anticoagulation increase the odds of delayed hematuria after PVP, while older age is protective.

References

Mamoulakis C . A plea for higher-quality data for GreenLight laser technology in the context of surgical benign prostatic obstruction trials: the GOLIATH study-fact or fiction in the era of evidence-based urology?. Eur Urol. 2013; 65(5):943-5. DOI: 10.1016/j.eururo.2013.11.037. View

Sandhu J, Leong J, Das A . Photoselective vaporization of the prostate: application, outcomes and safety. Can J Urol. 2019; 26(4 Suppl 1):8-12. View

Thangasamy I, Chalasani V, Bachmann A, Woo H . Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012. Eur Urol. 2012; 62(2):315-23. DOI: 10.1016/j.eururo.2012.04.051. View

Schwartz R, Couture F, Sadri I, Arezki A, Nguyen D, Zakaria A . Reasons to believe in vaporization: a review of the benefits of photo-selective and transurethral vaporization. World J Urol. 2020; 39(7):2263-2268. DOI: 10.1007/s00345-020-03447-x. View

Bachmann A, Tubaro A, Barber N, dAncona F, Muir G, Witzsch U . A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study. J Urol. 2014; 193(2):570-8. DOI: 10.1016/j.juro.2014.09.001. View

Laine-Caroff P, Pradere B, Ruffion A, Bruyere F . Greenlight laser photoselective vaporization vs open simple prostatectomy: long-term functional outcomes after treatment of large volume prostates (> 80 cc). Int Urol Nephrol. 2021; 53(7):1289-1295. DOI: 10.1007/s11255-021-02839-1. View

Pradere B, Peyronnet B, Decock A, Brichart N, Bertrand P, Bruyere F . Photoselective Vaporization of the Prostate in Men With Refractory Urinary Retention. Urology. 2015; 86(1):145-50. DOI: 10.1016/j.urology.2015.04.020. View

Jackson R, Casanova N, Wallner L, Dunn R, Hedgepeth R, Faerber G . Risk factors for delayed hematuria following photoselective vaporization of the prostate. J Urol. 2013; 190(3):903-8. DOI: 10.1016/j.juro.2013.03.070. View

Peyronnet B, Pradere B, Brichart N, Bodin T, Bertrand P, Bruyere F . Complications associated with photoselective vaporization of the prostate: categorization by a panel of GreenLight users according to Clavien score and report of a single-center experience. Urology. 2014; 84(3):657-64. DOI: 10.1016/j.urology.2014.05.028. View

10.

Herr H . The enlarged prostate: a brief history of its surgical treatment. BJU Int. 2006; 98(5):947-52. DOI: 10.1111/j.1464-410X.2006.06397.x. View

11.

Ghobrial F, Shoma A, Elshal A, Laymon M, El-Tabey N, Nabeeh A . A randomized trial comparing bipolar transurethral vaporization of the prostate with GreenLight laser (xps-180watt) photoselective vaporization of the prostate for treatment of small to moderate benign prostatic obstruction: outcomes after 2 years. BJU Int. 2019; 125(1):144-152. DOI: 10.1111/bju.14926. View

12.

Reich O, Bachmann A, Siebels M, Hofstetter A, Stief C, Sulser T . High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol. 2004; 173(1):158-60. DOI: 10.1097/01.ju.0000146631.14200.d4. View

13.

Ruszat R, Wyler S, Forster T, Reich O, Stief C, Gasser T . Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol. 2006; 51(4):1031-8. DOI: 10.1016/j.eururo.2006.08.006. View

14.

Sandhu J, Ng C, Gonzalez R, Kaplan S, Te A . Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol. 2005; 19(10):1196-8. DOI: 10.1089/end.2005.19.1196. View

15.

Stafinski T, Menon D, Harris K, Md G, Jhangri G . Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia. Can Urol Assoc J. 2008; 2(2):124-34. PMC: 2422913. View

16.

Bruyere F, Huglo D, Challacombe B, Haillot O, Valat C, Brichart N . Blood loss comparison during transurethral resection of prostate and high power GreenLight(™) laser therapy using isotopic measure of red blood cells volume. J Endourol. 2011; 25(10):1655-9. DOI: 10.1089/end.2011.0104. View

17.

Bouchier-Hayes D, Van Appledorn S, Bugeja P, Crowe H, Challacombe B, Costello A . A randomized trial of photoselective vaporization of the prostate using the 80-W potassium-titanyl-phosphate laser vs transurethral prostatectomy, with a 1-year follow-up. BJU Int. 2009; 105(7):964-9. DOI: 10.1111/j.1464-410X.2009.08961.x. View

18.

Tanchoux C, Pereira H, Brichart N, Bruyere F . [Perioperative and early postoperative results of photoselective vaporization of the prostate using fiber 4090 (providing 120 watts) versus fiber MOXY (providing 180 watts)]. Prog Urol. 2012; 22(9):529-33. DOI: 10.1016/j.purol.2012.04.012. View

19.

Ajib K, Mansour M, Zanaty M, Alnazari M, Hueber P, Meskawi M . Photoselective vaporization of the prostate with the 180-W XPS-Greenlight laser: Five-year experience of safety, efficiency, and functional outcomes. Can Urol Assoc J. 2018; 12(7):E318-E324. PMC: 6118054. DOI: 10.5489/cuaj.4895. View

20.

Eken A, Soyupak B . Safety and efficacy of photoselective vaporization of the prostate using the 180-W GreenLight XPS laser system in patients taking oral anticoagulants. J Int Med Res. 2018; 46(3):1230-1237. PMC: 5972269. DOI: 10.1177/0300060517747489. View